Zinc supplements are widely used to boost immunity and treat deficiencies, but taking too much can cause nausea, nutrient ...

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, research has demonstrated that combining ADT with additional agents ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

Early-stage prostate cancer rarely causes symptoms, making routine screening the most reliable way to catch it before it ...

Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that returned after radiotherapy. Matched analyses estimated 10-year ...

SEOUL, Feb. 10 (UPI) --The world's leading non-ferrous metal manufacturer, Korea Zinc, said it posted record earnings in 2025, extending its long-standing track record of profitability. The ...

UCLA researchers have developed a mineral sunscreen formulation that significantly reduces the white, chalky cast that keeps many people from wearing sun protection daily. For decades, dermatologists ...

Super Bowl champions Bruce Arians and Rob Gronkowski star in a cheeky Super Bowl ad from Novartis designed to encourage men to get screened for prostate cancer with an easy blood test. Arians and ...

LONDON, Jan 27 (Reuters) - Zinc failed to perform to script last year and the galvanising metal continues to surprise in the first days of 2026. A market that was supposed to transition to oversupply ...

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in minimally invasive, focal treatment options has been growing for certain ...

The National Institute for Health and Care Excellence (NICE) has recommended a new oral treatment for men with untreated hormone-relapsed metastatic prostate cancer. NICE assessed evidence from the ...